GB201916838D0 - Method of diagnosis - Google Patents
Method of diagnosisInfo
- Publication number
- GB201916838D0 GB201916838D0 GBGB1916838.4A GB201916838A GB201916838D0 GB 201916838 D0 GB201916838 D0 GB 201916838D0 GB 201916838 A GB201916838 A GB 201916838A GB 201916838 D0 GB201916838 D0 GB 201916838D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
- G01N2405/08—Sphingolipids
- G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916838.4A GB201916838D0 (en) | 2019-11-19 | 2019-11-19 | Method of diagnosis |
| EP20796910.6A EP4022316A1 (en) | 2019-10-21 | 2020-10-20 | Method of diagnosis of a neurodegenerative disease |
| PCT/GB2020/052632 WO2021079098A1 (en) | 2019-10-21 | 2020-10-20 | Method of diagnosis of a neurodegenerative disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1916838.4A GB201916838D0 (en) | 2019-11-19 | 2019-11-19 | Method of diagnosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201916838D0 true GB201916838D0 (en) | 2020-01-01 |
Family
ID=69063297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1916838.4A Ceased GB201916838D0 (en) | 2019-10-21 | 2019-11-19 | Method of diagnosis |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4022316A1 (en) |
| GB (1) | GB201916838D0 (en) |
| WO (1) | WO2021079098A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2473176A4 (en) * | 2009-09-04 | 2013-03-06 | Univ Alberta | NEUROPROTECTIVE COMPOUNDS, COMPOSITIONS, METHODS AND KITS |
-
2019
- 2019-11-19 GB GBGB1916838.4A patent/GB201916838D0/en not_active Ceased
-
2020
- 2020-10-20 EP EP20796910.6A patent/EP4022316A1/en not_active Withdrawn
- 2020-10-20 WO PCT/GB2020/052632 patent/WO2021079098A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021079098A1 (en) | 2021-04-29 |
| EP4022316A1 (en) | 2022-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE061482T2 (en) | Method of synthesis | |
| GB201804724D0 (en) | Method of diagnosing cceliac disease | |
| GB202000926D0 (en) | Method of diagnosis | |
| GB201802795D0 (en) | Patient assessment method | |
| GB201804594D0 (en) | Bonegraft substituteand method of manufacture | |
| GB201802839D0 (en) | Method of manufacture | |
| GB201916046D0 (en) | Diagnostic method | |
| GB202005231D0 (en) | Method of mimimising patient risk | |
| IL287250A (en) | Method of treatment | |
| GB202102823D0 (en) | Diagnostic method | |
| SG11202105877YA (en) | Method of treatment | |
| GB202000634D0 (en) | Diagnostic method | |
| GB201918853D0 (en) | Methods of treatment | |
| GB201904861D0 (en) | Diagnosis | |
| GB201903055D0 (en) | Method of oligonucleaotide synthesis | |
| IL290983A (en) | Methods of treatment | |
| GB201509658D0 (en) | Method of diagnosis | |
| GB201916838D0 (en) | Method of diagnosis | |
| GB201903424D0 (en) | Method of diagnosis | |
| GB201902193D0 (en) | Method of diagnosis | |
| GB201910444D0 (en) | Methods of diagnosing cancer | |
| GB201911056D0 (en) | Treatment of ADD/ADHD | |
| GB201809456D0 (en) | Method of diagnosis | |
| GB201615330D0 (en) | Method of diagnosis | |
| GB2609987B (en) | Diagnostic method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |